XOMA Corporation (XOMA) : During the past 4 weeks, traders have been relatively bearish on XOMA Corporation (XOMA), hence the stock is down -2.02% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.65% relative to the S&P 500. The 4-week change in the price of the stock is -4% and the stock has fallen -12.19% in the past 1 week.
The stock has recorded a 20-day Moving Average of 7.07% and the 50-Day Moving Average is 4.39%.The 200 Day SMA reached 30.05% XOMA Corporation has dropped 2.34% during the last 3-month period . Year-to-Date the stock performance stands at -57.41%.
XOMA Corporation (XOMA) : The highest level XOMA Corporation (XOMA) is projected to reach is $3 for the short term and the lowest estimate is at $1. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $1.62 and the possibility the share price can swing is $1.2.
Company shares have received an average consensus rating of Hold for the current week XOMA Corporation (NASDAQ:XOMA): stock was range-bound between the intraday low of $0.53 and the intraday high of $0.6 after having opened at $0.6 on Fridays session. The stock finally closed in the red at $0.6, a loss of -15.13%. The stock remained in the red for the whole trading day. The total traded volume was 4,445,255 shares. The stock failed to cross $0.6 in Fridays trading. The stocks closing price on Thursday was $0.5664.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).